A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NAVIGATE-AD)
The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Your participation could last approximately 1 year and include 19 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must present with mild AD dementia
- Participant must have adequate venous access for blood draws
- Participant must be willing and able to undergo MRI and PET scans
- Participant must not have significant neurological disease affecting the central nervous system (CNS), other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy